Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Two five-color fluorescence multiplex amplification systems of 13 Y chromosome short tandem repeat (Y-STR) loci (DYF387S1, DYF399S1, DYF403S1a/b, DYF404S1, DYS449, DYS518, DYS526a/b, DYS547, DYS570, DYS576, DYS612, DYS626, and DYS627) have been designed. A study was conducted measuring the mutation rates of the 13 Y-STRs in 501 father-son pairs of Han origin in Beijing, China. Among 7515 allele transmissions in 501 father-son pairs, 75 single-step and 2 two-step mutations were observed. Two father-son pairs had mutations at two different loci in 13 Y-STRs. The estimated mutation rates ranged from 2.00 × 10 (95% CI 1.00 × 10 to 1.11 × 10) for the DYF387S1, DYF403S1b, DYS526a, and DYS449 loci to 4.59 × 10 (95% CI 2.93 × 10 to 6.81 × 10) for the DYF399S1 locus. The average mutation rate is 1.02 × 10 (95% CI 8.10 × 10 to 1.28 × 10). Among these Y-STR markers, only DYF399S1, DYS627, DYF403S1a, DYS547, DYS612, and DYS626 had mutation rates higher than 1.00 × 10.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00414-018-1949-7 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
First-Line Aumolertinib in -Mutant Advanced Non-Small Cell Lung Cancer: A Multicenter Real-World Retrospective Study with a Four-Year Follow-Up.
Oncol Res
September 2025
Department of Oncology, Affiliated Hospital of Guilin Medical University, Guilin, 541001, China.
Background: The use of third-generation different tyrosine kinase inhibitors (TKIs) is considered the most effective option for treating advanced non-small cell lung cancer (aNSCLC) with epidermal growth factor receptor (EGFR) mutations. However, there is limited information on the efficacy and safety of aumolertinib in patients remains these cases.
Methods: The clinical records of patients receiving aumolertinib as first-line therapy across four hospitals in the Guangxi Zhuang Autonomous Region from April 2020 to December 2021 were retrospectively analyzed, using progression-free survival (PFS) as the primary endpoint and overall survival (OS) representing the secondary endpoint.
Comparative efficacy and safety of therapeutic strategies for EGFRvIII positive recurrent glioblastoma.
iScience
September 2025
Beijing Institute of Brain Disorders, Laboratory of Brain Disorders, Ministry of Science and Technology, Collaborative Innovation Center for Brain Disorders, Capital Medical University, No.10 Xitoutiao You'anmenwai Fengtai District, Beijing 100069, P.R. China.
Glioblastoma multiforme (GBM) is the most aggressive primary brain tumor, and EGFRvIII mutation has been associated with treatment resistance and poor prognosis, highlighting the need for more effective therapeutic strategies. We conducted a random-effects Bayesian network meta-analysis to compare the efficacy and safety of treatments for EGFRvIII-positive recurrent GBM (rGBM), evaluating overall survival (OS), progression-free survival (PFS), and objective response rate (ORR). Seven clinical trials were included ( = 716).
View Article and Find Full Text PDFPhenotype and genotype in hereditary chronic intestinal pseudo-obstruction with small intestine involvement.
Front Med (Lausanne)
August 2025
Department of Gastroenterology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Chronic intestinal pseudo-obstruction (CIPO) is a rare and severe intestinal motility disorder with poor long-term prognosis and high mortality rate, especially when the small intestine is involved. Due to the non-specificity of clinical symptoms, CIPO has long faced diagnostic challenges. With the advancements of sequencing technology, many hereditary CIPOs have been identified.
View Article and Find Full Text PDFEnhancing diagnostic efficiency of pyrazinamide resistance in via modified MGIT assay and genotypic correlation.
Curr Res Microb Sci
August 2025
Department of Immunology, ICMR-National Institute for Research in Tuberculosis, Chennai, India.
Pyrazinamide (PZA) plays a crucial role in the treatment of both active and latent tuberculosis, particularly in regimens designed to treat drug-resistant TB. However, diagnosing resistance to PZA poses challenges for managing TB, highlighting the need for accurate detection methods. This study aims to address the challenges in detecting PZA resistance by modifying the standard MGIT960 PZA drug susceptibility testing method by optimizing the inoculum dilution.
View Article and Find Full Text PDFWithin-host population dynamics of extensively drug-resistant revealed by an over 3-year longitudinal study.
Evol Med Public Health
July 2025
National Clinical Research Center for Infectious Diseases, Shenzhen Clinical Research Center for Tuberculosis, Shenzhen Third People's Hospital, Shenzhen, China.
Background And Objectives: Drug resistance is a major contributor to tuberculosis (TB) deaths worldwide. Understanding the dynamics of in-host evolution of (MTB) drug resistance can help to improve treatment success rates.
Methodology: The microevolution of drug-resistant MTB was studied in three patients with long-standing, extensively drug-resistant TB (XDR-TB) by analyzing whole genome sequences of serial isolates collected during treatment.